Member Info for Matml74

Enjoy!

https://www.webmd.com/coronavirus-in-context/video/stephen-holgate

The company has clearly stated that EUA application is happening in the US first and that is where the highest demand for the drug will initially be.

The protocol is new for P3 trial it wasn't an extension of the P2 trial.

Theres a few things that have changed compared to P2. SOC for hospitalised patients has improved so this may result in a difference in efficacy compared to placebo. However SNG has really narrowed down the patient cohort in the P3 to a group that they know they see the biggest effect of SNG001 ie. breathless needing oxygen. They have seen significant differences compared to placebo for this group of patients in asthma, COPD and two Covid trials. This is why I have confidence the P3 will produce a positive outcome.

Doc,

The detail on how the data is analysed is in the protocol which Synairgen produced so they have had their input. The statistical methods to be used were defined off the back of the P2 trial by Synairgen. Parexel have a large data analysis division so this shouldn't be a time limiting factor.

We have the timeframe specified by the company as early 2022 so thats when it will be IMO.

Doc, They also have an obligation to shareholders not to screw it up. They are using Parexel/data magic for the analysis. It is not being done in house. First point of call is data cleaning which I expect to take a week. Remember they have data across 17 countries and any irregularities/discrepancies in the data need to be picked up and corrected during this cleaning stage.

Forcing your own timelines onto these things will only put undue stress on any decisions you may make around buying/selling your shareholding. Trust in the company to do it correctly is the most important thing. They will be doing everything in their power to get it done in a timely manner.

Discussion of vaccines is sooooo 2020...... Guess what 2 more days until the data unblinds :-)

SNG001 to save the world!

Trial set to start before Xmas. Some logistical issues getting all trial sites set up and trained on administration of drug was the last info provided.

This was provided by one of the members last week so don’t shoot the messenger if it is wrong :-)

The only thing anyone knows is SNG are currently recruiting a second Director of CMC. The first CMC director was put in place mid year. This would suggest the company some clarity on forward orders but this has not been revealed to the market.

It used to be vaccines. Now it’s a mild variant. Whatever. Those that have been here long enough understand the science, the size of the market and the importance of the drug in this pandemic and future ones as well.

Eventually this drug will be standard of care for anyone needing hospitalisation for a viral lung infection, but first it will deal with covid.

JP Morgan made the same call this time last year.....

"Global growth will be below trend in early 2021, but the strongest global recovery in a decade will play out by the end of 2021 if the vaccine prospects play out as expected,” said Joyce Chang, Chair of Global Research."

I agree totally. Just won’t happen unfortunately.

They can’t unblind as there are 35 day secondary endpoints.

Can you sort the Magna rns out please Soulboy :-)

Yes possibly.

Nature yesterday...

“In summary, we have shown that SARS-CoV-2 exhibits broad tropism for nasal epithelial cells, but with preferential infection of ciliated and secretory cell types. Nasal cells mount a robust innate antiviral response to SARS-CoV-2 dominated by paracrine IFN-I/III signalling, which is delayed in onset relative to viral replication, but which is nevertheless capable of exerting partial control at later times post-infection. Upon exposure to exogenous IFN-I/III treatment, these cells adopt a profound antiviral state, highlighting a potential clinical role for recombinant IFNß or IFN?1 in chemoprophylaxis and/or therapy of COVID-19.”

https://www.nature.com/articles/s41467-021-27318-0

Excellence, The citadel short was closed on 19th Jan not reduced. You will see on shorttracker it is at 0% after 19th Jan on the graph. They have just taken a new short position on the 6th Dec at 0.5%.

It’s structured as a press release so I don’t think so. However it’s possible they may rns as there are some numbers in there that are different to the May rns. Gamma is new news (although mentioned yesterday) and the May rns used concentrations required for 90% viral reduction whereas this press release talks about 99% viral reduction but sng001 concentrations required are higher.

Hopefully this gets some press coverage tomorrow as a minimum. Start the PR ramp up.

https://www.synairgen.com/umbraco/Surface/Download/GetFile?cid=126178bc-9907-4a26-af78-87817f710401

Because thats what scientists do Doc. They present data to the scientific community at conferences. The rns was to notify that.

Anyway I hear they presentation will be released later today according to a member on reddit.

But you were informed yesterday what was being discussed. SNG001 use in asthma and COPD. The data is all on the website.